One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering....
Here is how Actinium Pharmaceuticals (ATNM) and Encompass Health (EHC) have performed compared to their sector so far this year....
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 17, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at developments for t...
- Actimab-A enhances dose-dependent acute myeloid leukemia cell death in KMT2A sensitive acute myeloid leukemia blasts in combination with leading menin inhibitors - Combination with leading menin inh...
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive...
- Novel targeted radiotherapy-based combination being studied as potential backbone therapy potential relapsed or refractory acute myeloid leukemia - Actimab-A + CLAG-M produced high rates of response...
Biotech stocks are always interesting from a trading perspective. With dozens of companies in the clinical-stage, positive news from trials can be a big catalyst for a scintillating rally....
Iomab-B led bone marrow transplant improved survival in patients with high-risk relapsed or refractory acute myeloid leukemia including those with a TP53 mutation Iomab-B safely delivered radiation to...
In a meme frenzy, any positive news related to a company has a magnified impact on the stock price. In the euphoria of 2021, companies with ambitious growth plans skyrocketed....
- KOL and principal investigator, Dr. Farrukh Awan, Professor of Medicine, Division of Hematology Oncology at University of Texas Southwestern to join Actinium management on the webinar - Webinar ...
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive ...